Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients.
Adolescent
Adult
Aged
Aged, 80 and over
Apyrase
/ biosynthesis
Biomarkers
/ analysis
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
/ pathology
Female
Hepatitis A Virus Cellular Receptor 2
/ biosynthesis
Humans
Iran
Lymphocyte Count
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ biosynthesis
SARS-CoV-2
/ immunology
Young Adult
CD39
COVID-19
Exhausted cell
PD-1
TIM-3
Journal
Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
13
10
2020
revised:
28
01
2021
accepted:
29
01
2021
pubmed:
7
2
2021
medline:
13
4
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
During viral infection, inhibitory receptors play a key role in regulating CD8 T-cell activity. The objective of this research was to investigate programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), and CD39 exhaustion markers in CD8 T cells of new coronavirus disease-2019 (COVID-19) patients. A total of 44 patients with COVID-19 (17 subjects in a critical group and 27 patients in a non-critical group) and 14 healthy controls, who were admitted to Hospitals in Babol, were recruited to the study. In subjects' peripheral blood mononuclear cells (PBMCs), we compared the phenotype of CD8 T lymphocytes, expressing PD-1, TIM-3, or CD39, both alone and in various combinations. The findings showed that the percentage of CD8 Patients, infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), altered exhausted CD8 T lymphocytes with CD39 and TIM-3 exhaustion markers, which may account the dysregulated immune response found in COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
During viral infection, inhibitory receptors play a key role in regulating CD8 T-cell activity. The objective of this research was to investigate programmed cell death protein 1 (PD-1), T-cell immunoglobulin and mucin domain-containing protein-3 (TIM-3), and CD39 exhaustion markers in CD8 T cells of new coronavirus disease-2019 (COVID-19) patients.
METHODS
METHODS
A total of 44 patients with COVID-19 (17 subjects in a critical group and 27 patients in a non-critical group) and 14 healthy controls, who were admitted to Hospitals in Babol, were recruited to the study. In subjects' peripheral blood mononuclear cells (PBMCs), we compared the phenotype of CD8 T lymphocytes, expressing PD-1, TIM-3, or CD39, both alone and in various combinations.
RESULTS
RESULTS
The findings showed that the percentage of CD8
CONCLUSION
CONCLUSIONS
Patients, infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), altered exhausted CD8 T lymphocytes with CD39 and TIM-3 exhaustion markers, which may account the dysregulated immune response found in COVID-19.
Identifiants
pubmed: 33548481
pii: S0882-4010(21)00051-6
doi: 10.1016/j.micpath.2021.104779
pmc: PMC7857983
pii:
doi:
Substances chimiques
Biomarkers
0
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Apyrase
EC 3.6.1.5
ENTPD1 protein, human
EC 3.6.1.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104779Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
PLoS One. 2010 Mar 04;5(3):e9504
pubmed: 20209097
JCI Insight. 2020 May 21;5(10):
pubmed: 32324595
Front Immunol. 2018 Apr 09;9:678
pubmed: 29686673
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8
pubmed: 20679213
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Front Immunol. 2014 Apr 16;5:171
pubmed: 24795718
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Microb Pathog. 2019 Mar;128:323-328
pubmed: 30660734
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Pathogens. 2019 Sep 11;8(3):
pubmed: 31514485
J Virol. 2009 Sep;83(18):9122-30
pubmed: 19587053
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
PLoS Pathog. 2010 May 06;6(5):e1000882
pubmed: 20463811
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519
J Exp Med. 2008 Nov 24;205(12):2763-79
pubmed: 19001139